Featured article: The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics
There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery (EMIF-AD MBD) study. We confirm the central roles of Aβ and APOE ε4 in AD pathogenesis. The results of the multimodal analyses will provide new insights into underlying mechanisms and facilitate the discovery of new diagnostic and prognostic AD biomarkers.
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Alzheimer's blogs from BMC
Advertisement
Affiliated with
-
Alzheimer's Research & Therapy is affiliated with Alzheimer's Disease International (ADI), London, United Kingdom.
2017 Journal Metrics
-
Speed
50 days from submission to first decision
123 days from submission to acceptance
29 days from acceptance to publication
Citation Impact
5.015 - 2-year Impact Factor
6.206 - 5-year Impact Factor
1.511 - Source Normalized Impact per Paper (SNIP)
2.449 - SCImago Journal Rank (SJR)Usage
472,895 downloads
720 Altmetric mentions
Advertisement
